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Introduction: Dual-energy X-ray absorptiometry is rarely utilized in the clinical care of patients with complex
regional pain syndrome, but may be useful for the non-invasive determination of regional bone fragility and
fracture risk, as well as muscular atrophy and regional body composition. This is the first report in the literature of
complex regional pain syndrome and musculoskeletal co-morbidities in an athlete, and is the first to focus on
dual-energy X-ray absorptiometry for the clinical assessment of complex regional pain syndrome.
Case presentation: In this report, we describe the case of a 29-year-old Caucasian man with type 1 complex
regional pain syndrome. His body mass index was 29.4kg/m2 at the time of presentation. Despite severe complex
regional pain syndrome in the left limb and long term use of a wheelchair, the patient participated in high-performance
powerlifting. Dual-energy X-ray absorptiometry revealed marked unilateral differences in bone strength and lean mass
between the affected regions and the contralateral regions. Low bone mineral density for age was found in the left hip,
with Z-scores ranging from −2.2 to −3.0, and the patient had previously suffered two fractures. Bone density Z-scores in
the right hip and legs were normal.
Conclusions: Dual-energy X-ray absorptiometry is a valuable tool for the clinical investigation of musculoskeletal health
in patients with complex regional pain syndrome. Regional osteoporosis in complex regional pain syndrome patients is
complicated and should be investigated and monitored. Physical activity is possible for some complex regional pain
syndrome patients, depending on the type of exercise and the region affected, and it may protect bone density and
strength at non affected skeletal sites.
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Complex regional pain syndrome (CRPS) can be trig-
gered by peripheral trauma, fracture, surgery, or spon-
taneously and causes significant functional morbidity.
The International Association for the Study of Pain (IASP)
[1] defines CRPS type I as “a syndrome that usually de-
velops after an initiating noxious event, is not limited to
the distribution of a single peripheral nerve, and is appar-
ently disproportionate to the inciting event. It is associated
at some point with evidence of edema, changes in skin
blood flow, abnormal sudomotor activity in the region of* Correspondence: k.hind@leedsmet.ac.uk
1Carnegie Research Institute, Leeds Metropolitan University, Headingley
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distribution, and reproduction in any mediumthe pain, or allodynia or hyperalgesia” (p 41).The common
symptoms of CRPS include extreme reactions to touch;
tremor; pain and temperature; impaired movement; muscle
spasms; change in skin color; hair and nail growth; pseudo-
paralysis, paresis; and autonomic, sensory and vasomotor
symptoms [1-4]. The inability to participate in physical ac-
tivity and a reduced quality of life are consequences of
these symptoms. There is no consensus regarding treat-
ment, mainly because of the clinical heterogeneity of CRPS.
Common pharmaceutical therapies include pain medica-
tion, local anesthetics, intravenous sympathetic blockades,
bisphosphonates, calcium channel blockers, spinal cord
stimulation and amputation [1,2,4-6].
Of the CRPS comorbidities, region-specific osteoporosis
and muscle hypotrophy may also be considered as object-
ive indicators of the disease, although there is a lack ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
Table 1 Anthropometry and bone status
Characteristics Patient data
Height 171.4cm
Weight 86.3kg
Body mass index 29.4kg/m2
Body fat 26%
Total body bone mineral density Z-score −0.1
Total hip bone mineral density Z-score −1.4
Hind and Johnson Journal of Medical Case Reports 2014, 8:165 Page 2 of 5
http://www.jmedicalcasereports.com/content/8/1/165published data on this topic. Osteoporosis is a systemic,
skeletal disease characterized by low bone density and
microarchitectural deterioration of bone tissue with a con-
sequent increase in bone fragility. Osteoporotic fractures
are the clinical endpoints of bone fragility and carry sig-
nificant mortality and morbidity. Such musculoskeletal
entities associated with CRPS [7] are likely to develop in
response to disuse due to immobilization and can cause
further pain, fracture and disability. It has been reported
that CRPS-associated bone loss is characterized by ele-
vated bone turnover and bone resorption [8]. Extensive
type 1 and type 2 muscle fiber atrophy, as well as neuro-
genic myopathy, have also been reported in CRPS patients
[9,10]. Dual-energy X-ray absorptiometry (DXA) may be use-
ful for noninvasive, accurate determination of demineralization
of bone and fracture risk in CRPS patients. With the re-
cent advances in DXA technology, this tool may also be
useful for the determination of CRPS-associated muscular
atrophy and unilateral body composition.
Case presentation
A 29-year-old Caucasian man presented to our institu-
tion for DXA investigations. He met the IASP criteria
for CRPS and was medically diagnosed with type I CRPS.
His symptoms associated with CRPS were first reported
at the age of 10 years following orthopedic surgery to the
left hip. That surgery was initiated after he had been diag-
nosed with Calve-Perthes disease at the age of 9 years. Re-
habilitation from the surgery was unsuccessful, and he
remained wheelchair-bound thereafter because of inability
to move his left leg, accompanied by severe, localised pain.
There was blue discoloration to the affected limb , and the
patient had abnormal hair and toenail growth as well as
swelling. His other chronic complaints included severe
pain while taking a shower, bruising, and insomnia due to
pain. Numerous orthopedic and pediatric physicians con-
firmed that his Perthes disease was no longer a problem
following surgery. The patient had been diagnosed with
CRPS at age 13 years. He had fractured his left fifth meta-
tarsal at age 17 years, and he fractured to his left patella
at age 24 years. Sensitivity tests conducted at a pain
management unit in 2011 revealed marked mechanical
allodynia induced by the lightest monofilament (finer than
a hair) and hypersensitivity to a pinprick with lasting
tingling in the left leg. He received different methods
of pain treatment, including guanethidine blocks, which
helped only initially for approximately one week. Subse-
quent treatments included opioids and spinal cord
stimulation. Combinations of drugs were prescribed for
neuropathic pain, but produced little benefit. The patient
had also taken antidepressants (fluoxetine hydrochloride)
for several months at age 17 years. At the time of
our assessment, the patient was taking amitriptyline,
co-codamol and diclofenac.The long-term symptoms and comorbidities of CRPS
can often lead to inability to perform activities of daily
living, which usually means that participation in physical
activity and high-level sports is not possible. Our patient
engaged in regular upper-body resistance exercise train-
ing and performed competitively at the international
level. He had been participating in the competitive sport
of powerlifting for more than three years, despite his se-
vere CRPS symptoms.
The patient was measured while wearing lightweight
clothing and no jewelry. His height was measured to the
nearest millimeter using a stadiometer (seca United
Kingdom, Birmingham, UK), and his body weight was
recorded to the nearest 0.1kg with calibrated electronic
scales (seca United Kingdom). DXA was performed
using a fan-beam Lunar iDXA imager (GE Healthcare,
Madison, WI, USA) in standard mode. The machine’s
calibration was checked and passed on a daily basis prior
to the scanning session using the GE Lunar calibration
phantom. There was no significant drift in calibration
prior to the scanning session. For the total body scan,
the patient was placed in the supine position on the
scanning table with his body aligned with the central
horizontal axis. His arms were positioned parallel to, but
not touching, the body, with his legs fully extended. His
feet were not secured with the usual support so as not
to cause him any distress. For the total hip scan, the pa-
tient was again positioned supine on the scanning table.
His arms were placed across his chest, and his feet were
placed on either side of the dual femur positioning sup-
port. His feet were not strapped, but rather were inwardly
rotated to obtain an optimal scan image. The total hip
scan also enabled hip structural analysis (HSA) to gain
information on the structural geometry and strength
of the patient’s left proximal femur. Section modulus,
cross-sectional area (CSA (in cm2); exclusive of soft-
tissue spaces) and cross-sectional moment of inertia re-
sults were obtained using HSA. The duration of the total
body scan was 7 minutes, and the total hip scan, 2 minutes.
The scans were analyzed using the Lunar enCORE soft-
ware version 13.6 (GE Healthcare).
The patient’s general results are shown in Table 1. The
results for his regional body bone mineral content (BMC)
and lean tissue mass (LTM) are shown in Table 2. Figure 1
Table 2 Regional bone mineral content and lean tissue
mass derived from total body dual-energy X-ray
absorptiometry
Bone mineral content (g) Lean tissue mass (kg)
Limb Left Right Difference Left Right Difference
Arms 264 270 −6 5.3 5.3 0
Trunk 470 559 −89 15.2 14.6 0.5
Legs 331 511 −180 6.7 10.6 −3.9
Total 1,296 1,682 −386 28.8 32.9 −4.1
Data were obtained using a Lunar iDXA (GE Healthcare, Madison, WI, USA).
Figure 1 Lunar iDXA image taken from a total body scan of a male a
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clearly visible unilateral differences in bone and muscle
mass. DXA revealed gross muscle wasting of all muscle
groups in the left leg. Visual analysis of the scan indicated
that his left leg was much shorter than his right leg. Con-
currently, the largest unilateral differences in BMC and
LTM were found in the legs, with lower mass in the left
legs equivalent to 36% and 37% for BMC and LTM, re-
spectively. This did not affect his total body BMD, which
was 1.190g/cm2, giving an overall normal Z-score of −0.1.
Table 3 shows the unilateral differences in hip the
patient’s BMD and the corresponding Z-scores. The
lowest Z-score was −3.0. Differences in BMD between
the left and right sides of the hip ranged from 19% to
31% (left < right), and the Z-scores on the left sidethlete with complex regional pain syndrome of the left limb.
Table 3 Unilateral bone mineral density of the total hip
and regions of the hip in the patient’s left leg
Bone mineral density (g/cm2) Age-matched Z-score
Body region Left Right Difference Left Right
Femoral neck 0.781 0.965 −0.184 −2.3 −0.8
Wards Area 0.634 0.832 −0.199 −2.6 −1.0
Trochanter 0.598 0.863 −0.265 −3.0 −0.6
Total 0.760 1.055 −0.295 −2.6 −0.3
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according to the International Society for Clinical
Densitometry (for men 50 years of age and younger).
Table 4 provides the results from the DXA-derived
HSA and shows distinct differences in bone geometry
between the left and right proximal femurs.
Discussion
We recommend the incorporation of DXA measure-
ments in the clinical care of patients with CRPS. Our
DXA investigations revealed large bone and LTM differ-
ences between the affected and contralateral regions.
The bone density in the patient’s left leg and left hip was
low, and his bone geometry was compromised, poten-
tially exposing him to greater risk of fragility fracture in
the affected regions. Of interest, the patient had also
previously had fractures to the left fifth metatarsal and
the left patella at ages 17 years and 24 years, respect-
ively. His bone density was normal at non-CRPS sites,
which suggests that participation in regular exercise
training involving unaffected regions of the body may be
of benefit for maintaining bone strength. This case re-
port also demonstrates that participation in high levels
of targeted exercise is possible for CRPS patients, de-
pending on the site affected.
DXA is a viable imaging test for CRPS patients both
practically and technically, because it is objective and
noninvasive, requires minimal patient preparation, can
be performed quickly has a high level of accuracy. Min-
imal patient preparation is particularly important, given
the pain often experienced during CRPS clinical investi-
gations. Clinically, DXA can be used to assess for osteo-
porosis according to the World Health Organization
guidelines [11] and provide objective information onTable 4 Unilateral differences in hip structural analysis
parameters of the patient’s left proximal femur
Measurements Left Right Difference
Section modulus (mm3) 802.8 897.7 −94.9
Cross-sectional moment of inertia (mm4) 16.8 17.8 −10
Cross-sectional area (mm2) 154 179 −25asymmetrical regional bone and body composition. Al-
though regional osteoporosis associated with CRPS may
be transient, our patient’s low Z-scores and age suggest
that bone therapeutic intervention may be of value, es-
pecially bearing in mind that he had had CRPS for
19 years with no sign of recovery to date. Our patient
was 29 years of age upon presentation to our institution,
when he was reaching the end of the peak bone mass ac-
crual period. The failure to attain optimal peak bone
mass during childhood and young adulthood increases
the risk of osteoporosis and fracture later in life. Patients
with osteoporosis may benefit from pharmaceutical in-
terventions to improve bone mass and prevent further
bone loss and osteoporotic fracture, which, independ-
ently of CRPS, can cause significant pain and disability.
Bisphosphonates (risedronate, pamidronate and alendro-
nate) are used widely to treat osteoporosis because of
their potent inhibitory effect on bone resorption, and
they are now recognized for their analgesic properties in
the treatment of CRPS [12,13].
Unfortunately, for our patient, no baseline DXA exam-
ination reports of bone density and lean mass prior to or
in the early stages of CRPS development were available.
This information would have been useful to track how
much bone and lean tissue had been lost (or not gained
during bone mass accrual with age) through immobilization
due to CRPS, the rate of loss, as well as any possible sys-
temic factors. Although it has been suggested that patients
with osteoporosis are more susceptible to CRPS [14], the
findings in our patient suggest that he acquired regional
osteoporosis as a consequence of CRPS rather than vice
versa. This was indicated by the marginal unilateral differ-
ences in tissue mass between the left and right limbs.
Upon referral, longitudinal DXA monitoring of this pa-
tient will enable us to gain insights into the progression
(or a plateau) of bone loss with the persistence of the dis-
ease or bone gain with recovery from CRPS.
Conclusions
DXA is a valuable tool for the clinical investigation of
musculoskeletal health in patients with CRPS. Regional
osteoporosis in CRPS patients is complex and should be
investigated and monitored. Therapy aimed at improving
bone density in affected patients should be considered.
Physical activity is not completely out of the question
for CRPS patients, depending on the type of exercise
and the region affected, and may protect bone density
and strength at non-CRPS sites.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. The patient’s sports coach also provided informed
consent, and both the patient and his coach were
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